The greatest potency was observed against NCI-H226 (considered inconclusive for p53 status) non-small cell lung cancer, SF-539 CNS (inconclusive for p53 status) cancer, SK-MEL-28 melanoma (p53 mutation L145R), and MDA-MB-435 breast cancer (all with LC50 values less than 10 nM). This evidence concerns the gene TP53 and breast carcinoma.